Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
conjugated estrogens/progestin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| conjugated estrogens/progestin (MPA) | DRUG | - |
Inclusion Criteria: * Healthy, postmenopausal women ages 35 to 70 years, inclusive. * Naturally postmenopausal women must not have had a menstrual period for at least six months, but less than 12 months, as confirmed by a blood test; or for at least 12 months with no blood hormone test confirmation...
Conjugated estrogens/progestin is a small molecule combination therapy being developed by Pfizer for estrogen replacement therapy. It pairs conjugated estrogens with a progestin component, medroxyprogesterone acetate. The combination is designed for use in the endocrine therapeutic area and has been studied in a Phase 1 bioavailability trial.
Conjugated estrogens/progestin is used for estrogen replacement therapy. It combines conjugated estrogens with medroxyprogesterone acetate, a progestin, in a single regimen. The clinical program has focused on this endocrine indication, with a completed Phase 1 study conducted in healthy female volunteers aged 35 years and older.
Conjugated estrogens/progestin targets the estrogen receptors ESR1 and ESR2 as an agonist. The estrogen component binds and activates these receptors, while the progestin component, medroxyprogesterone acetate, complements the combination. This receptor activity underlies its use in estrogen replacement therapy.
Pfizer, Inc. develops conjugated estrogens/progestin. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company is the sponsor behind the clinical development of this conjugated estrogens and medroxyprogesterone acetate combination for estrogen replacement therapy.
Conjugated estrogens/progestin is in Phase 1 development. It is an investigational combination and is not approved for marketing based on the development stage reported. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
Conjugated estrogens/progestin has been studied in one completed Phase 1 trial, NCT00401219. That randomized, uncontrolled study compared the bioavailability of three new formulations of Premarin/MPA against the Premarin/MPA (PREMPRO) reference formulation in healthy female volunteers aged 35 years and older, under the condition of estrogen replacement therapy.